Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis
CD137 ligand activated microglia induces oligodendrocyte apoptosis via reactive oxygen species.
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.
Multiple sclerosis.
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.
[A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis].
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Shorter washout reduces MS relapse switching off natalizumab
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Pregnancy outcomes in female patients and partners of male patients in the teriflunomide clinical development program.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
Valproic acid ameliorates inflammation in experimental autoimmune encephalomyelitis rats.
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.
Amyloid precursor protein at node of Ranvier modulates nodal formation.
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.
Control of experimental autoimmune uveoretinitis by low dose T cell vaccination.
Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Suppression of Murine Experimental Autoimmune Optic Neuritis by Mature Dendritic Cells Transfected with Calcitonin Gene-Related Peptide Gene.

Pages